Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors

Author:

Giri Smith12,Grimshaw Alyssa3,Bal Susan2,Godby Kelly2,Kharel Prakash4,Djulbegovic Benjamin5,Dimopoulos Meletios A.6,Facon Thierry7,Usmani Saad Z.8,Mateos María-Victoria9,Costa Luciano J.2

Affiliation:

1. Institute for Cancer Outcomes and Survivorship, Division of Hematology and Oncology, University of Alabama at Birmingham

2. Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham

3. Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, Connecticut

4. Department of Hospital Medicine, Geisinger Health System, Geisinger, Danville, Pennsylvania

5. Evidence-based Analytics and Comparative Effectiveness Research, Department of Supportive Care, City of Hope Comprehensive Cancer Center, Duarte, California

6. Section of Hematology and Medical Oncology, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

7. Department of Hematology, Lille University Hospital, Lille, France

8. Plasma Cell Disorders Program, Levine Cancer Institute/Atrium Health, Charlotte, North Carolina

9. Department of Hematology, University Hospital of Salamanca/IBSAL, Cancer Research Center, Salamanca, Spain

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3